GW Pharmaceuticals Initiates Phase 3 Trial for Multiple Sclerosis Drug
GW Pharmaceuticals (NASDAQ: GWPH) announced today that it is starting up its phase 3 trial for nabiximols, an oral spray for patients who have spasticity associated with multiple sclerosis (MS). Nabiximols is a botanical medicine derived from cannabis plants. The drug, sold as Sativex outside the U.S., has already been approved in over 25 countries around the world for this indication, including in the U.K. and Canada.
In a press release, CEO Justin Gover said that he sees "a clear path to [a New Drug Application] submission, potentially as soon as next year, and a significant second product opportunity for GW in the U.S." Two years ago, GW saw its first cannabis-derived drug, Epidiolex, approved for use in the U.S. for patients who have rare forms of epilepsy. The Food and Drug Administration has recently expanded its approval for that drug.
Image source: Getty Images
Source Fool.com
